IPN60190 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
94Primary sclerosing cholangitis1

94. Primary sclerosing cholangitis


Clinical trials : 148 Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2022-002695-37-ES
(EUCTR)
13/02/202310/01/2023A study on safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Adults patients with Primary Sclerosing Cholangitis (PSC)
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Product Code: IPN60190; GFT505
INN or Proposed INN: Elafibranor
Product Code: IPN60190; GFT505
INN or Proposed INN: Elafibranor
Ipsen Bioscience, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2Canada;United States;Italy;United Kingdom;France;Portugal;Germany;Spain